Prefacing with prior information from 9 days ago:

The important "rest of the story" you need to know regarding NRx Pharmaceuticals (NRXP) and the anticipated upcoming ANDA approval for preservative-free IV ketamine

Catalyst 1: ANDA approval

• Since all that was needed was an "attestation" from the luer lock vial manufacturer (see above link), I think the maximum time to approval would be akin to a Class 1 CRL, which is 60 days from the GDUFA meeting that took place on July 29.
• Approval can happen any day now. With great likelihood, it will be prior to Sep 30.
• Per the CEO, NRx is ready to ship vials in very large quantities. It will bring in substantial revenue.
• The potential for NRx to take a huge ketamine market share in a relatively short amount of time is REAL, as it's the ONLY preservative-free ketamine that will be available, it has a 100% domestic supply chain, and the ability to currently manufacture 1M vials per month, with room to increase production with a goal of eliminating shortages of this U.S. strategic drug.

Catalyst 2: NDA submission for NRX-100 (preservative-free IV ketamine formulation for psychiatric use)

• If they are granted Priority Review, the PDUFA date will be 6 months from the FDA's acceptance of the NDA, which could mean around April/May 2027.
• If they are granted the Commissioners National Priority Voucher (CNPV), which they have applied for, then the PDUFA date would be 60 days or less from the date of the FDA's acceptance of the NDA.
  • According to NRx, NRX-100 meets the criteria for the CNPV (which does not mean they will be granted it).
• NRX-100's NDA filing was originally projected for Dec 2025. The good news is the proposed indication was expanded earlier this year after a meeting with the FDA, likely causing much of the delay. The CEO recently alluded to the filing occurring very shortly (I believe it will be in Sep 2026). He confirmed NRx will be including the luer lock vial attestation from the manufacturer to avoid that snag for NRX-100.
• In the above link, there is a link to the Aug 10 NRx shareholder update call, where the CCO states the ketamine/esketamine market is projected to be $3B in 2027.

H.C. Wainwright, which tends to be on the high side of the price target range, reiterated their $45 PT a week ago. Last year, other analysts' PTs were between $25 and $34.

The share price should act accordingly upon ANDA approval with a very-near-term share price of $10 to $12 seemingly very reasonable based upon the facts and conservative projections.

Three months left to the PDUFA date, and the share price hasn't budged. Here is my complete thesis on Polypid, and why I see a 6x from here.

Guys, I think I just noticed a textbook case of reflexivity - PSNL, Personalis.

This tiny and very little known company powers the engine behind the recently hyped Merck-Moderna cancer vaccine.

Despite the huge revenue upside from the vaccine, the stock has barely performed after the news, due to its previous merger agreement with Tempus at $16.25, which was BEFORE the vaccine update and is still pending shareholders’ vote.

This is where things get interesting- after the vaccine news, PSNL stock broke through $16.25 and has been trading at a slight premium over the buyout price for 7 days in a row. And over 40% of outstanding shares have been traded above the buyout price as of today.

Due to its tiny scale and the huge revenue upside from the vaccine, I think it’s safe to assume impressive returns if the deal was to fall apart. And the more shares traded above the buyout price and the higher the share price goes, the less likely is the merger to go through. The situation feels exactly like what George Soros described in Alchemy of Finance - the higher the volume and share price, the higher the share price will climb. And based on its recent trading, I think some big boys might have been making this bet.

The shares trades at only about 3% premium over $16.25, worth taking a shot? Any thoughts?

Stocktwits Ceo gone on one -seems like its time.

112 days at record 56 day event rate...

At 115 days or by next week sep 03 the event rate will be 57.5 or achieve more than double the 60 to 78,
28.72 day event rate

It will be a massively valuable milestone...this week may be the ONE...believe 79th event occurred in july on or before july 20th.

Hello everyone, sharing an important update:

An active settlement fund is currently accepting claims from investors who experienced financial losses in CytoDyn.

The settlement involves claims that CytoDyn misled investors about the regulatory status, safety, and effectiveness of leronlimab, its HIV and COVID-19 drug candidate. After an FDA statement in March 2021 criticized the company’s claims, $CYDY fell more than 25%.

If you purchased or acquired $CYDY common stock between 2020 and 2022, you may be eligible to file a claim.

Anyway, has anyone here invested in $CYDY during that time? How much were your losses, if so?

Intuitive Surgical makes the da Vinci robotic surgical system, along with the Ion platform for lung procedures. Surgeons control robotic arms to perform minimally invasive surgery with more precision and smaller incisions than traditional techniques allow. The company pioneered this category and still dominates it decades later.

The business model is the actual story here. Selling or leasing the robot itself isn't where the real money is. Every procedure performed on a da Vinci system requires new instruments and accessories, and those get repurchased continuously as hospitals keep using the machine. In Q1 2026, instruments and accessories revenue made up the majority of total revenue and grew 23% year over year, roughly in line with procedure volume growth. Recurring revenue overall made up 86% of total revenue in Q1. Once a hospital buys a multi-million dollar robot and trains its surgeons on it, switching to a competing platform is a genuinely difficult, expensive decision, which is exactly what makes the recurring revenue so durable.

The installed base keeps expanding too: 11,710 da Vinci systems worldwide as of Q2 2026, up 12% year over year, with the newer da Vinci 5 platform running about 11% higher utilization than the previous generation Xi system. Q1 revenue was $2.77 billion, up 23%, and Q2 came in at $2.89 billion, up 19%, with non-GAAP EPS nearly doubling from $2.19 to $2.80 year over year in Q2 alone.

Here's the part that genuinely surprised me. Despite that strong Q2 beat, the stock fell about 10% after hours because management kept full-year da Vinci procedure growth guidance unchanged at 13.5-15.5%, rather than raising it again like they had after Q1. That would represent the company's slowest procedure growth in several years, and the market read "no raise" as a red flag even with double-digit growth and margin expansion sitting right there in the actual results.

The real risks with Intuitive Surgical are genuine: China and Japan are seeing slower growth from lower tender activity and domestic competition, US bariatric procedures actually declined about 10% as GLP-1 drugs reduce demand for weight-loss surgery, and rising memory and tariff costs are pressuring gross margins for the rest of the year. The stock trades at 44x forward earnings, below its own decade-long average multiple, which some read as a genuine value opportunity in a durable moat business, and others see as fair given the growth deceleration. Anyone holding through the guidance disappointment?

https://x.com/adamfeuerstein/status/2094473302299259221

A famous and mostly correct bio stock poster. Why are all the popular bio stock posters short? Hm

Hello I Have a SaaS company that runs a website for Biotech Companies and catalysts. I am looking for 1-2 People who know the sector, including PDUFA dates, Clinical trials, News etc. The only thing I can offer at the moment is a free trial and free services but this could and probably will turn in to a paid service (meaning pay you as a QA expert int his space) DM me.

The stock is severely undervalued trading around 1.35 right now, but the average analyst price target is around 12 right now.

https://ir.ocugen.com/static-files/f414c2d5-19c4-487f-9198-91e61c4971d8

Retinis Pigmentosa is the big phase 3 catalyst coming Q1 2027 and Stargardt Disease is the interim analysis coming out Q3 2026 and the full data coming out in H1 2027. There is severe unmet need here curing blindness and the phase 2 data is actually very good.

Later in 2028 there will be a big geographic atrophy phase 3 data release.

Overall the stock is extremely undervalued compared to the good probability of success and huge TAM.

Do your own research. Put 30% of my portfolio here because of the fast realization of the coin flip coming. Big results fast.

I'm guessing from what I've seen lately (as an outsider mind you) that advances in multi-omics and other types of predictive software suites in biomedicine ought to result in less uncertainty for baby biotechs?

Not to mention whatever new diagnostic technologies come about along the way. Is A.I. getting sufficiently better at viewing the world of medical/academic "big data" in a less hallucinatory way, and synthesizing "do's and don'ts" of drug design more effectivley? Or for that matter, realistic measures of where innovation is most needed and/or most profitable?

Wishing you all an optimistic view of the next week and a Sunday you can get lost in 🙂

Hello Everyone,

I was reading some of GMDAs old documents about their small molecule NAM technology. That is a licensable product. If it enhances stem cells in culture then why wouldn’t it enhance other cell types in culture? This was shown with the company looking into their NK cell immunotherapy.

This could be paired with current marketed CAR-T drugs like Kymriah(tm) to see if patients with exhausted starting cultures could be “rejuvenated.” This could be paired with monocyte cultures to see how dendritic cell cultures perform for DC vaccines.

That said, the big thing with Gamida’s tech is its “off the shelf“ view of their NAM formula for other cell lines. That “idea” is just another thing for shareholder value.

if you want a comparison product look up RPMI medium. everyone uses it.

Completed first-cycle FDA review of the Company's ANDA for preservative-free ketamine with no drug-related major deficiencies. The sole remaining item, a manufacturer's attestation on the vial, has been submitted to FDA.

Initiation of commercial scale manufacturing of preservative-free ketamine building to launch stock of 5 million doses to be ready for commercialization in 2026.
Selected by the Defense Advanced Research Projects Agency (DARPA) as prime contractor for SPARC-TMS, an FDA-approved Phase 2/3 trial of NRX-101 with robotic TMS. Anticipated non-dilutive funding exceeds $11.5 million, subject to completion of contracting

The Company is advancing its NRX-100 NDA on Real World Evidence from more than 65,000 patients, leveraging a Presidential Executive Order and Congressional budget language that encourage FDA use of such evidence in approving treatments for depression.

Key development has been advancement of the ANDA for preservative-free ketamine toward FDA approval and commercialization, which would represent a transformational milestone . The FDA identified no major deficiencies related to the drug or its manufacture. A single major deficiency was identified related to the luer lock component of the vial (i.e. the element of the drug container that connects to a syringe) wherein FDA requested that the Company provide a manufacturer's attestation that the vial is manufactured in the same manner as it is for 3 other currently approved drugs that ship more than 11.9 million units per year. This attestation has been provided to the FDA and the Company aims for 2026 approval and commercialization. Accordingly, five million units of launch stock is currently in the manufacturing process with anticipated post launch manufacture of 1 million units per month.

I thought this update on their PHASE 1A trial was extremely solid.

The original 2025 data showed at the highest dose:

ANGPTL3: −73%
TG: −55%
LDL: −49%

Now, one year later, the mean ANGPTL3 reduction is actually 79%, LDL is 53%, and TG remains 48%. Triglyceride numbers were slightly worse but not significant.

Good data and no additional adverse events, showing both durability and safety. Great readout, now need data on a larger human population. 15 patients was a small sample size, but the proof of concept of in-vivo editing worked. The durability is better than simply seeing an initial biomarker response—it starts demonstrating the fundamental value proposition of a one time gene editing.

Yet the market didn’t seem to care and stock still dumped😂 what am I missing?

Personalised cancer vaccines are suddenly getting a lot of attention, particularly following the recent developments involving $MRNA and $MRK. $BNTX, $SLS and $IBRX are also getting attention from investors interested in cancer vaccines and immunotherapy.

But one name seems to receive surprisingly little mainstream attention: Northwest Biotherapeutics ($NWBO) and its personalised dendritic-cell therapy DCVax-L for glioblastoma (GBM).

DCVax-L isn't an mRNA vaccine — it's a different approach to personalised cancer immunotherapy. However, it has already completed a Phase 3 trial and published its results, whereas some of the cancer-vaccine programmes currently attracting significant attention are still progressing through clinical development.

The other unusual part is where DCVax-L currently sits: the UK regulatory process. NWBO submitted its Marketing Authorisation Application to the MHRA in December 2023, and the application remains under review.

We're now approaching 1,000 calendar days since submission.

I'm not saying that means approval is guaranteed — far from it. I'm genuinely curious why DCVax-L isn't being discussed more alongside the broader cancer-vaccine sector, particularly now that personalised cancer vaccines are becoming such a major investment theme.

Is the lack of attention simply because NWBO is an OTC company and relatively small, or are investors overlooking a potentially important cancer-vaccine programme?

I'd be interested to hear from people who follow the oncology/biotech space, including anyone who has looked closely at DCVax-L.

Helus is the cheapest late-stage psychedelic developer by a wide margin and is currently trading quite below my assessed value (risk-adjusted DCF plus a verified transaction layer); the value is bimodal and the mid-November readout is the focus. Please dig holes but I am really confident, and I wanted to share my thesis below. Esp on today's sell off on XBI - i think it's the right time to make some short term to medium term gains, a minimum double bagger.

Helus (formerly Cybin) is developing HLP003, a deuterated form of psilocin taken as two oral doses three weeks apart, as an adjunctive treatment for major depressive disorder — meaning patients keep taking their existing antidepressant, the broadest label being pursued by any psilocybin-class developer. Its first pivotal trial (APPROACH, 223 patients) reports topline inmid-to-third-week November 2026; the second (EMBRACE, 330 patients) in 2027.

I have run deep dives from a multi-modal view which include:

1. Phase 2 → Phase 3 translation study: the formal statistics of how depression-trial effects shrink between phases (this is quite important because of HELP's own phase 2 results - which some of you might know were pretty interesting, more on this below, and I"ll paste the screenshots in the comments as it doesn't let me post more than one image) around a reference class of thirteen psychiatry programs
2. A review of Adjunctive-dosing evidence: (including controlled SSRI-interaction trials, pharmacology around receptor occupancy, and the concomitant-antidepressant literature)
3. ATAI's acquisition by Lilly + the new CEO's own acquisition past
4. A detailed deep dive around the comparison of APPROACH's design against FDA's final psychedelic guidance - which it matches on every design element (durability characterisation the one partial)
5. Thought I'd also do some checks around trial websites, any leaks from investigators, flow and socials

What makes me highly confident on this is that there's:

1. The class works, and is now 4-for-4 in Phase 3: COMPASS's two pivotals (3.6 and 3.8 points against control in treatment-resistant depression), and Definium's two (8.1 points in MDD; a positive anxiety pivotal in August) have all met their primary endpoints.
   1. The drug WILL engage its target: at the pivotal 16 mg dose, serotonin-2A receptor occupancy is ~92–94% — saturated — so the pharmacology is robust to patient-to-patient variability and to background SSRIs, which two randomized trials show do not blunt psilocybin's core effects
   2. The statistics favour significance: my model readout has an 83% probability of statistical significance and a 69% probability of printing above COMPASS's 3.6–3.8 — because APPROACH's significance threshold is only ~2.9 points, a level even a heavily shrunk Phase 2 effect clears
   3. The regulatory path is being cleared by others, faster than I thought a few weeks ago: COMPASS's rolling NDA carries a National Priority Voucher targeting a one-to-two-month review — the first psilocybin approval decision could land in early 2027, about two years before Helus files, and FDA's final guidance explicitly endorses the adjunctive, no-washout design Helus chose
   4. A verified acquisition benchmark now exists: Lilly paid ~$2.8bn upfront (~$2.6bn net of cash) for atai Beckley at Phase-2b-complete — one full stage earlier than Helus will be in November — and J&J's $14.6bn purchase of Intra-Cellular shows what the commercial endpoint of this label is worth. At $13.24 the market is discounting a ~52% probability of approval under the basest of the base case; every listed peer trades at 1.6–5.1× Helus's fully diluted value

Of course it goes without saying, readout must still be respected as a binary.

The magnitude of the Phase 2 effect (13.7 points) will not survive: the counted comparables shrank 47–77% in the dramatic-small-Phase-2 bucket (and even the 'held' cases shrank at matched timepoints), Phase 3 adjunctive placebo arms move −8 to −13 points against Cybin's −2.7, and no adjunctive program in history had entered Phase 3 with a Phase 2 effect above 9 points, Helus is off the class map.

My expected printed effect is ~5.2 - 6 points; the two collapse cases in the adjunctive class (pimavanserin, ALKS- 5461) both came from small, enriched, big-delta Phase 2s — the bucket Helus's Phase 2 belongs to — and I'd hold a 20% weight on a collapse state (a ~17% overall probability of a statistical miss). The market's bar, set by a 13-point narrative, $62–70 price targets and a +75% five-week run, sits near 5–6 points: a 4–5-point print would match the best approved drug in the category and could still trade down hard, as COMPASS's did (−49% on a statistically clean result). And the success path needs ~$1.35bn of external capital; the Intra-Cellular template says a follow-on lands within days of a good print.

For those who are new and do not know much about the company:

Helus Pharma is the operating name of Cybin Inc., a Toronto-headquartered, Nasdaq-listed clinical- stage company (~100 employees) built through acquisitions (Adelia, a deuterated psychedelic chemistry; Small Pharma: DMT assets) and repeated equity financings, including a 1-for-38 share consolidation in September 2024 — today's $13 is roughly 90% below the 2021 bubble peak on an adjusted basis, a history that matters for supply and sentiment.

Its value is almost entirely HLP003 (formerly CYB003), an orally administered deuterated psilocin (psilocin-d10) in Phase 3 for adjunctive MDD with FDA Breakthrough Therapy Designation (March 2024). Behind it sit HLP004 (deuterated DMT, intramuscular; positive Phase 2a signal in generalised anxiety reported March 2026) and discovery assets.

Michael Halstead, formerly President of Intra-Cellular Therapies, which J&J bought for $14.6bn in 2025, became CEO on 3 August 2026; ex-Intra-Cellular executives now also fill the Chief People Officer seat and the scientific advisory board (Suresh Durgam, the former Intra-Cellular CMO whose name is on the best adjunctive-MDD trials ever run). The company is telling the Intra-Cellular story deliberately; I've tried to test this here to see if it's repeatable or not.

WHY I AM EXTREMELY CONFIDENT:

1. The efficacy question is "how much , not "whether this will happen"
   1. Serotonergic psychedelics have a replicated pivotal record: COMPASS's COMP005 (−3.6 MADRS points vs placebo, p<0.001, n=258) and COMP006 (−3.8 vs 1 mg, n=581) in treatment-resistant depression, and Definium's LSD (−8.1 at Week 6, n=149) in MDD (Major Depressive Disorder). For reference, a ~2-point placebo-adjusted MADRS difference has historically supported antidepressant approvals, and the best approved drug in Helus's exact category — adjunctive MDD — is lumateperone (Caplyta) at 4.5–4.9 points.
   2. HLP003's randomized Phase 2 separated by 14.1 (12 mg) and 13.0 (16 mg) points at Day 21 in the same adjunctive population APPROACH enrols. That number will of course shrink: I applied the formal winner's-curse correction (which removes only ~16–23% for a result this statistically extreme), the counted placebo-normalisation effect (Phase 3 adjunctive placebo arms move −8 to −13 points; Cybin's 13-patient Phase 2 placebo arm moved −2.7), and the class's realised transition ratios.
   3. The result is a three-state readout model — effect holds (~6.8 points, 42%), shrinks to the class norm (~4.8, 38%), collapses (~2.8, 20%) — giving an expected print of ~5.2 - 6 points, an 83% probability of statistical significance, and a 54% probability of clearing the ~5-point bar I believe the market carries
2. At 16 mg, HLP003 produces ~92–94% occupancy of the serotonin-2A receptor — past the knee of the occupancy curve — and the same is true of the competing plasticity target (TrkB, ~95%). A saturated dose cannot fail for pharmacokinetic reasons, is robust to halving of exposure, and — per two randomized crossover trials of psilocybin and LSD after SSRI pre-treatment (escitalopram 14 days; paroxetine 42 days) — is not blunted by the background antidepressants APPROACH patients stay on; if anything the SSRI reduces the anxiety and adverse effects of the session [Becker et al. 2022 and 2025]. The corollary cuts both ways: saturation means the drug's higher exposure versus 25 mg psilocybin (1.41× peak levels at the doses compared, not the 2.2× per-mg figure in company materials) buys at most +0.3–0.75 MADRS points — HLP003 is psilocin with tidier kinetics, not a stronger drug (Debate 1)
3. Adjunctive MDD is the broadest label in the class, pursued exactly the way FDA asked. Patients stay on their antidepressant against a matched inert placebo; the program uses remote, independent raters blinded to treatment and dosing experience, firewalled session reporting, two trained monitors per session, prospective abuse-related adverse-event collection, and expectancy and treatment-guess instruments. FDA's final psychedelics guidance (July 2026) names each of these; APPROACH matches the guidance on every named design element (durability the one partial), including its most specific recommendation (central raters blinded to allocation and visit number) and its explicit warning against unnecessarily excluding patients on concurrent antidepressants — a de facto endorsement of the adjunctive design (Debate 2). The label pool — inadequate response to at least one adequate antidepressant course — is ~5m US adults, ~1.5–1.7× the treatment-resistant pool COMPASS addresses
4. Regulatory risk is being retired by the leader, on the leader's dime, faster than I thought at initiation. COMPASS completes its rolling NDA in Q4 2026 under a Commissioner's National Priority Voucher targeting a 1–2 month review: the first psilocybin approval decision plausibly lands in early 2027 — roughly two years before Helus files — and answers the class-level questions (unblinding, REMS shape, DEA rescheduling, durability language) at COMPASS's expense. An April 2026 Executive Order directs FDA and DEA to accelerate exactly this class. I assign 83% to approval given a clean two-trial package, ~87% blended across sequencing scenarios, and ~61% overall.
5. Payers already fund monitored psychiatry at ~$20k+ per patient-year, and two acquirers have now marked the space. Spravato (esketamine) — two hours of in-clinic monitoring per dose, no durability claim — reached $1.7bn in 2025 across >5,000 certified sites. Caplyta's adjunctive-MDD approval (Nov 2025, on 4.5/4.9-point trials) re-accelerated it to a ~$1.4bn run-rate under J&J. And the two transactions that bracket Helus's endgame are now counted facts: Lilly–atai Beckley (~$2.8bn upfront at Phase-2b-complete, July 2026) and J&J–Intra-Cellular ($14.6bn at 21.5× revenue after five years of commercial proof). I assume $8,500 net per dose, 89k US patients at peak (3% of the serviceable pool — Spravato-parity penetration on a broader label), and $2.4bn peak revenue in 2043
6. At $13.24 the market cap equals the smallest transaction comp in the class (Otsuka– Transcend, $1.2bn) and implies ~52% approval probability — no longer the deep discount of June, but a discount nonetheless.

KEY RISKS:

1. Final distribution puts ~17% on a statistical miss and ~14% on a "significant but <4 points" print; both would take the stock to $2–7. A 4–4.5-point result — clinically approvable, matching Caplyta — would likely trade down 25–40% initially: COMPASS fell 49% on a statistically clean 3.6 (Debate 4). The expectations backdrop has worsened since initiation: price targets of $62 (TD Cowen) and $70 (H.C. Wainwright) are now in circulation, the company's 13–14-point Phase 2 numbers anchor every retail thread, and the stock has already re-rated +75% in five weeks on zero new drug information
2. The placebo arm is the single decisive unknown.
   1. Phase 3 adjunctive-MDD placebo arms move −8 to −13.4 points (it was −13.4 that killed cariprazine's second pivotal); psychedelic-trial placebo arms move −1 to −7. APPROACH's population is adjunctive-MDD at 45 commercial sites — the placebo-inflating profile — mitigated by central rating and an independent severity-confirmation gate at screening. Nobody has ever run this arm before; it is 20 of my 20 collapse points.
3. The Phase 2 anchor is the fragilest in the class.
   1. One blinded timepoint (Day 21), 36 patients, 3 sites, a 13-patient placebo arm, no peer-reviewed publication of any human CYB003 data (posters and press releases only), a formulation bridge (liquid→capsule) that fails formal bioequivalence at 10 mg with no patient bridge at 16 mg, and a Phase 3 dose (16 mg ×2) that was the weakest cell of its own Phase 2 at the pivotal timepoint — chosen for durability shown in seven patients. Every one of these is survivable; together they are why my collapse weight is 20% and not 10%.
4. Durability is not resolved by this readout.
   1. The registry's MADRS schedule ends at Day 42; the company states the topline will include the key secondary (Week 12 per its communications) — I'll flag the discrepancy rather than resolve it. Either way, the 12-month "100% response / 71% remission" headline rests on 7–8 open-label completers; real durability evidence arrives with EMBRACE in 2027.
5. Financing.
   1. ~$145m of cash covers ~4 quarters; the success path needs ~$1.35bn of external equity through 2031. Readout-linked warrants (9.2m at $8.14) expire 30 days after topline; a $100m at-the-market facility is in place and untouched; the Intra-Cellular template (a $500m raise the morning after its best readout) is the base case for the day after a good print.
6. Competition for the same chairs.
   1. Third-to-fifth to market behind COMPASS (TRD, 2027), Definium (LSD; two positive pivotals) and Lilly's BPL-003 (5-MeO-DMT, ~2-hour session — the reason Lilly bought it and spun the psilocin asset out of the same deal). An 8-hour session sets HLP003's clinic economics against the shortest-session competitor money can now buy.

CATALYST CALENDAR

BASE CASE MODEL ASSUMPTIONS AT A GLANCE:

Bull case — $52. APPROACH prints ≥6 points with an ordinary placebo arm; EMBRACE replicates with doseresponse; the National Priority Voucher program pulls launch to 2029. Peak penetration 4.0%, $9,500 net per dose, 2.6 doses per patient-year, exclusivity to 2044; PoS 68%; 11.5% discount rate; peak revenue ~$4.1bn. In this state a strategic sale is the likelier realisation path than a hold-to-launch: the counted precedents (Lilly–atai at ~$2.8bn upfront one stage earlier; J&J–Intra-Cellular at the commercial endpoint) support a bid in the $33–45 range after two positive trials — below the $52 standalone bull, but 2.5–3.4× today's price with the binary resolved.

Base case — $18. APPROACH significant at 4–7 points; EMBRACE confirms; approval 2029, launch 2030. Peak penetration 3.0% (89k patients), $8,500 net/dose, 2.4 doses per patient-year, exclusivity to 2043; PoS ~61%; 12.5% discount rate. Success value $24.6/share; failure ~$1–2.5; risk-adjusted DCF $15.6–15.9; transaction layer +$1.5–3.0 → $18. Peak revenue $2.4bn.

KEY QUESTION 1: How compelling is the HLP003 data, and what will APPROACH show?

Overview: HLP003 has one randomized dataset — a 36-patient, three-site Phase 1/2a cohort showing a 13–14- point placebo-adjusted MADRS reduction at Day 21 — and uncontrolled follow-up in seven patients out to a year. The pivotal tests two 16 mg doses against placebo (composition not publicly characterised) in 223 patients with a Week-6 primary endpoint.

Street's take: Targets of $16–70 treat Phase 2 as a strong prior; none I could obtain discloses a methodology.

My take: The signal is real, the pivotal is better powered than commonly assumed, and the magnitude will shrink — the only questions are by how much and through which mechanism. Final distribution: 83% probability of significance, 69% of beating COMPASS's 3.6–3.8, 54% of clearing ~5, 38% of ≥6; expected print ~5.2 points - 6 points.

Mechanism and molecule

Psilocybin is a prodrug the body converts to psilocin, a serotonin-2A receptor agonist whose acute action is believed to open a window of heightened cortical plasticity. HLP003 is psilocin, with ten hydrogens replaced by deuterium — slowing metabolism and skipping the conversion step, so onset is faster (~1 hour) and exposure more consistent. It does not change what happens at the receptor (5-HT2A binding equivalent to psilocin), and on the sponsor's own protocol it does not shorten the session: discharge is no earlier than eight hours post-dose. Two counted facts added this edition bound what the molecule can and cannot deliver. It will engage the target: published PET work maps plasma psilocin to receptor occupancy with a half-maximal concentration that puts psilocybin 25 mg at ~89–92% occupancy and HLP003 16 mg at ~92–94% — the dose sits past the knee of the curve, robust even to a halving of exposure, and the same arithmetic holds for the competing TrkB-mediated plasticity mechanism (~95% occupied). It cannot out-dose the class: because occupancy is saturated, HLP003's exposure edge over 25 mg psilocybin — 1.41× peak levels at the doses actually compared; the "2.2×" in company materials is a per-milligram figure — buys, on the only human exposure-response data in existence (COMPASS's 10 vs 25 mg arms: 1.3 points for an 11- occupancy-point step), roughly +0.3 to +0.75 MADRS points. HLP003 is psilocin with tidier kinetics. I underwrite it as such.

The Phase 2 data, and my read:

Five features determine how much weight the 13.7-point headline can carry. (1) One blinded timepoint. The placebocontrolled comparison ends at Day 21; the second dose was open-label (everyone received active drug), so the Day42 numbers, the response/remission rates and everything after have no control arm. (2) The placebo arm is 13 patients who moved −2.7 points — far below the −8 to −13 that modern multi-site adjunctive trials produce, and the single largest reason the delta will compress. (3) The dose-response is flat-to-inverted: 12 mg beat 16 mg on the placebo-adjusted delta (−14.08 vs −12.99) and on absolute change at both timepoints; at the exact Phase 3 regimen and timepoint (2×16 mg, Day 42) the Phase 2 change-from-baseline was the weakest of the four dose/timepoint cells. The pivotal dose was chosen for durability observed in seven 2×16 mg completers, not for acute effect. (4) The rating regime differed: the company describes remote, independent, blinded raters as measures implemented for the pivotal program; the Phase 2 print predates that regime, and the site-vs-central rating literature (see Methodology) associates site rating with 3–4 points of placebo-response inflation and threshold-score inflation at screening. (5) No peer-reviewed publication of any human CYB003 data exists — posters, press releases and a corporate deck only. None of these five kills the signal; together they are why it must be shrunk hard, and why my collapse state carries 20%.

I attacked "how much will 13.7 shrink" four independent ways.

• (a) Winner'scurse statistics: trial results that impress are partly lucky; the expected exaggeration depends on how statistically extreme the result was. Using the published empirical-Bayes machinery calibrated on 23,747 Cochrane trial results, a result as extreme as Cybin's Phase 2 (z≈4.6) carries an expected inflation of only 16–23% — the folklore "halve any Phase 2" applies to marginal results, not this one. Expected true Day-21 effect: ~10.5– 11.5 points. This correction, however, fixes only random error.
• (b) Systematic design drift: what the winner'scurse cannot fix is that Phase 3 differs by design — 3 sites become 45 (multi-centre trials run ~32% relatively higher placebo response), Day 21 becomes Day 42 (each added week ~+3% placebo response), and the 13- patient placebo floor normalises toward the adjunctive class's −8 to −13. Placebo normalisation alone compresses the delta to ~6–8 even if the drug's arm fully holds.
• (c) Realised in-class transitions, decomposed: COMPASS's famous 6.6→3.6 collapse splits into half timepoint-decay (visible inside its own Phase 3: week-3 5.2 → week-6 3.6) and half active-arm attenuation at scale (6.6→5.2 at matched week 3) — and, critically, none of it was placebo inflation (its Phase 3 control arms moved less than its Phase 2b's). Definium "held" because its Phase 2b already ran at Phase-3 scale on the same site class. Helus shares Definium's protect-features in kind (commercial-site continuity, identical population carried forward, central raters in the pivotal) but attempts the largest site scale-up in class history (3→45). The two-dose regimen partially neutralises timepoint decay — but only partially: COMPASS's two-dose trial ran APPROACH's exact schedule and the second dose restored the effect to its prior peak rather than deepening it (final week-6: 3.8 two-dose vs 3.6 single-dose).
• (d) A thirteenprogram reference class: across psychiatry Phase-2→3 pairs of the last decade, outright collapse occurred exclusively in daily-dose, small-effect or enrichment-design programs; among episodic/rapid-acting programs with large Phase 2 effects the record is five-for-five without collapse, and psychedelic Phase 3s specifically are four-for-four statistically positive. In the adjunctive-MDD subclass, the small-delta bucket translated at ~1.0× and the big-delta bucket at 0.23–0.53 with two collapses — and Helus sits in the big-delta bucket.

The adjunctive-dosing evidence base

The design's load-bearing scientific assumption — that dosing a psychedelic on top of a continued SSRI works — now rests on more than the company's own data. Controlled interaction trials: two randomized, placebo-controlled crossover studies from an independent academic group show SSRI pre-treatment (escitalopram 14 days; paroxetine 42 days) does not reduce the positive subjective effects of psilocybin or LSD and reduces their anxiety, "bad trip" and adverse cardiovascular effects — a tolerability tailwind, with no change to psilocin's pharmacokinetics. The dissociation in naturalistic data: large surveys consistently find SSRIs blunt the intensity of the psychedelic experience while depression outcomes remain similar — supported by case reports of full remission with no subjective psychedelic effect at all. If that dissociation holds, a gentler session with intact efficacy is a commercial feature, not a bug. Peer-reviewed adjunctive efficacy: COMPASS's own open-label study of psilocybin added to a continued SSRI in treatment-resistant patients (n=19, published in Neuropsychopharmacology) produced a 14.9-point Week-3 improvement with 42% response and remission — the authors themselves calling for exactly the comparatorcontrolled adjunctive trial APPROACH now is. The regulatory view: FDA's final guidance warns against unnecessarily excluding patients on concurrent antidepressants. What does not exist: any adequately powered randomized comparison of psychedelic-with-SSRI versus psychedelic-after-washout — APPROACH is the first pivotal test of the design in history, which is simultaneously its market opportunity and its residual risk. A tiny academic trial randomising psilocybin recipients to concurrent fluoxetine or placebo (n=24, Brazil) may report around the same time; at twelve patients per arm it can move headlines.

Statistical precision, and why the significance bar is lower than consensus assumes. The EMBRACE protocol powers on a MADRS change standard deviation of 12; COMPASS's published pivotal confidence intervals back-solve to SDs of 8–10, and Cybin's own Phase 2 arm-level effect sizes imply pooled SDs of ~5–6.5. At ~110 evaluable per arm, APPROACH's standard error is plausibly 1.25–1.70 (central ~1.45), making the two-sided 5% significance threshold ≈ 2.9 points — a level that even the reference class's harshest translation ratios leave intact. This is the quiet arithmetic underneath our 83%: statistical failure requires not ordinary shrinkage but the joint tail — COMPASS-scale active-arm attenuation and full placebo normalisation and the Phase 2 having been mostly artifact — simultaneously.

Sources:

ClinicalTrials.gov NCT06564818 (APPROACH; all 28 registry versions diffed), NCT06793397 (EMBRACE; 34 versions), NCT06605105 (EXTEND), NCT05385783 (Phase 2), NCT06898606; EU CTIS 2024-519270-40-00 and 2024-516805-22-00 (incl. redacted EMBRACE protocol); EMBRACE protocol CYB003-003 v1.3; Krempien et al. ACNP posters (M83 2023; 12-month 2024); ACNP 2022 preclinical poster; Helus/Cybin press releases (Jun–Aug 2026), Q1 FY2027 MD&A (SEC 6-K, 14 Aug 2026), 2026 AIF, AGM circular (19 Aug 2026), Form Ds; COMPASS Pathways: Phase 2b protocol (NCT03775200) and Goodwin et al. NEJM 2022; COMP005/COMP006 topline releases and Feb 2026 deck; FY2025 10-K; CNPV release; Q2 2026 results; Goodwin et al. Neuropsychopharmacology 2023 (COMP003, adjunctive openlabel); Definium DT120 Emerge and Voyage releases (Jun/Aug 2026); Raison et al. JAMA 2023; Rucker et al. Nat Med 2026 (PsiDeR); Mertens et al. JAMA Psychiatry 2026 (EPISODE); Hieronymus et al. JAMA Netw Open 2025; Becker et al. Clin Pharmacol Ther 2022 (escitalopram– psilocybin) and 2025 (paroxetine–LSD); Madsen et al. (psilocin PET occupancy); Holze et al. Clin Pharmacol Ther 2023 (psilocybin PK); adjunctive-class trial reports: Berman 2007/2009, Marcus 2008 (aripiprazole); Thase 2015 ×2, Hobart 2018 ×2 (brexpiprazole); Durgam 2016, Sachs 2023, Riesenberg 2023, Fava 2018 (cariprazine); lumateperone 501/502 releases and AJP 2025; Daly 2018, Popova 2019, Fedgchin 2019, Ochs-Ross 2020 (esketamine); Savitz 2021 and J&J MDD3001 release (seltorexant); Fava 2019, Acadia Jul 2020 (pimavanserin); Fava 2016, FORWARD program (ALKS-5461); translation-statistics literature: van Zwet et al. Stat Med 2021; Dechartres et al. BMJ 2013; Khin et al. J Clin Psychiatry 2011; BIO Clinical Development Success Rates 2011–2020; Furukawa et al. (placebo response); Kobak 2010, Williams 2015, Kobak 2008, Freeman 2017 (rating methodology); FDA "Psychedelic Drugs: Considerations for Clinical Investigations" (final, docket FDA2023-D-1987; Federal Register 14 Jul 2026); EO 14401 (18 Apr 2026); Lilly–atai Beckley 8-K and merger agreement (16 Jul 2026), DEFM14A (10 Aug 2026), atai Beckley 10-Q (Q2 2026); atai/Beckley BPL-003 Phase 2b release (1 Jul 2025); J&J–Intra-Cellular releases (13 Jan 2025) and Intra-Cellular 10-Ks/8-Ks 2019–2025; J&J quarterly results 2022–2026 (Spravato, Caplyta); NIMH 2021 NSDUH; USPTO; Financial Modeling Prep (quotes, statements, price history, 14–28 Aug 2026)

Ives been following this small startup for the last two years and have 140,000 shares. Read the news over the last year and what they are leading up to. They are OTCQB right now but that looks like its going to change soon.

[https://www.stocktitan.net/news/ADIA/\](https://www.stocktitan.net/news/ADIA/)